Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study

Giorgio Walter Canonica, 1 Giorgio Lorenzo Colombo, 2, 3 Paola Rogliani, 4 Pierachille Santus, 5 Claudia Pitotti, 6 Sergio Di Matteo, 3 Chiara Martinotti, 3 Giacomo Matteo Bruno 3 1Asthma & Allergy Clinic, Humanitas University, Milan, Italy; 2S.A.V.E. S.r.l. Studi Analisi Valutazioni Econo...

Full description

Bibliographic Details
Main Authors: Canonica GW, Colombo GL, Rogliani P, Santus P, Pitotti C, Di Matteo S, Martinotti C, Bruno GM
Format: Article
Language:English
Published: Dove Medical Press 2020-01-01
Series:Risk Management and Healthcare Policy
Subjects:
severe allergic asthma
healthcare costs
effectiveness
cost-utility
omalizumab
proxima study
Online Access:https://www.dovepress.com/omalizumab-for-severe-allergic-asthma-treatment-in-italy-a-cost-effect-peer-reviewed-article-RMHP

Internet

https://www.dovepress.com/omalizumab-for-severe-allergic-asthma-treatment-in-italy-a-cost-effect-peer-reviewed-article-RMHP

Similar Items